Lilly's $2.75B AI Deal Reshapes Drug Discovery Model

Eli Lilly’s landmark partnership with Insilico Medicine, potentially valued at $2.75 billion, represents a critical inflection point for the pharmaceutical industry, validating generative AI as a primary engine for drug discovery. This move goes far beyond using AI for data analysis; it establishes a scalable model for originating novel drug candidates entirely through computational methods. Coming amid intense pressure for pipeline innovation and the maturation of foundational platforms like DeepMind